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W
e have previously reported that
peri-transplant conditioning leads
to successful induction of renal allograft
tolerance via the mixed chimerism
approach in nonhuman primates (NHP)
and humans. However, this strategy
requires treatments beginning six days
prior to transplantation, which limits its
relevance only to living donor transplant
recipients. To extend the clinical applic-
ability of this approach, we developed a
novel regimen “delayed tolerance,” with
which the recipient initially undergoes
organ transplantation with conventional
immunosuppression, followed by condi-
tioning and donor bone marrow trans-
plantation (DBMT) at a later date. This
approach might be likened to “planting
flowers in a battle field.” That is, the
recipient’s immunologic environment
after organ transplantation is like a
battlefield filled with hostile innate and
adaptive immune-responses directed
against donor antigeneic specificities.
Implanting fragile donor hematopoietic
progenitors into this environment and
encouraging them to bloom in this
vicious field requires special treatments.
In our NHP studies recently published
in The American Journal of Transplanta-
tion, we showed that such “delayed
tolerance,” in fact, can be induced in
NHP through the mixed chimerism
approach, if specific modifications to
overcome/avoid donor-specific memory
T cell responses are provided. These
modifications include adequate depletion
of CD8 memory T cells and timing
of donor bone marrow administration
to minimize levels of pro-inflammatory
cytokines. This article addendum will
provide a short summary of the original
paper with our additional insights and
interpretations.
Introduction
Based on our rodent studies on mixed
chimerism,
1,2 we initially developed a
clinically relevant non-myeloablative pre-
parative regimen that permits the induc-
tion of mixed chimerism and renal
allograft tolerance when combined with
simultaneous donor bone marrow trans-
plantation (DBMT) in MHC fully-
mismatched cynomolgus monkeys.
3-5
This approach has been successfully
extended to HLA matched
6 or mis-
matched
7 clinical kidney transplantation.
In murine models, the primary mechanism
of tolerance induction through mixed
chimerism was shown to be via thymic
deletion. That is, donor derived dendritic
cells (DC) migrate to the recipient
thymus, where they induce negative
selection of donor reactive T cell clones.
1,8
Therefore, induction of stable mixed
chimerism appeared to be a prerequisite
for stable allograft tolerance through this
strategy.
2 However, the mixed chimerism
induced in primates with our non-myeloa-
blative regimen has always been transient
in nature, but nevertheless, essential to
induce renal allograft tolerance in this
model. This led us to conclude that the
mechanisms associated with induction of
tolerance in primates include peripheral as
well as central thymic deletion pathways.
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Our original protocol requires treat-
ment of subjects beginning six days prior
to organ transplantation,
3,5,7 which limits
its applicability to living donor transplant
recipients. Therefore, our next major goal
has been to develop a strategy that is
applicable to deceased donor organ trans-
plantation. We initially evaluated regimens
in which conditioning was begun within
24 hours of kidney transplantation (KTx).
However, simple compression of the previ-
ously effective six-day therapeutic protocol
into a 24-hour period failed to induce
chimerism and also led to unacceptable
toxicity (Fig.1D). We thus developed a
novel “delayed tolerance” approach, with
which the recipient initially undergoes
organ transplantation with conventional
immunosuppression, followed by condi-
tioning and donor bone marrow trans-
plantation (DBMT) at a later date. This
approach would potentially extend the
applicability of our regimen to not only
current recipients of deceased donor
transplantation but also to any recipient
of a previously transplanted allograft
from either a living or deceased donor, if
DBM is available. However, the “delayed
tolerance” strategy has the theoretical
disadvantage that donor-specific memory
T cells (Tmem) might have been elicited
despite administration of potent immuno-
suppressive agents during the interval
between transplantation and attempted
tolerance induction. Therefore, we have
extensively monitored Tmem subsets and
alloreactive Tmem responses in these
studies.
Memory T Cell Responses
Following Kidney Transplantation
with Conventional
Immunosuppression
Primates including monkeys subjected
to these experiments typically exhibit
rigorous heterologous Tmem responses
even before KTx.
9 In addition to naïve
T cell responses, these preexisting Tmem
that heterologously respond to alloantigens
may further impair induction of chimer-
ism and allograft tolerance. We thus
monitored recipient Tmem responses by
measuring cIFN or IL-2 production by
ELISPOT. Somewhat unexpectedly, the
initially high alloreactive Tmem responses
appeared to decline after KTx in a time-
dependent fashion. As shown in Figure2,
cIFN and IL-2 Tmem responses progres-
sively fell after KTx and became almost
undetectable by four months. Since third
party Tmem responses were relatively
preserved, this was not simply due to the
global effects of immunosuppression.
Development of such donor-specific
Tmem hyporesponsiveness has also been
reported in clinical KTx
10,11 and is specu-
lated to result from the interaction
between recipient lymphocytes and tolero-
genic graft parenchymal cells.
12 An alter-
native explanation is memory T cell
exhaustion by antigen exposure.
13 The
important point is that, if these
ELISPOT results truly reflect the in vivo
status of Tmem responses, induction of
chimerism might be even easier when
DBMT is delayed.
The Initial Conditioning Regimen
that was Successful
for Simultaneous Kidney
and DBM Transplantation
Failed to Induce Chimerism
in the Delayed Tolerance Approach
In the delayed tolerance, recipients initially
underwent KTx alone and were treated
with conventional immunosuppression
(tacrolimus, MMF and steroids). Four
months later, the recipients received our
standard conditioning regimen (low dose
total body irradiation, local thymic irradia-
tion, ATG and anti-CD40L mAb). With
this regimen, recipients of simultaneous
kidney and DBM transplantation
(SKBMT) consistently developed multi-
lineage chimerism and most achieved
long-term survival without immuno-
suppression.
5 In contrast, no recipients
conditioned at four months with the same
therapeutic regimen developed multiline-
age chimerism (Fig.3C) and all rejected
their previously well-functioning kidney
allografts soon after discontinuation of
Figure 1. Renal allograft survival in the delayed tolerance (deaths due to infectious complication
censored). Simple compression of the previously effective 6-d therapeutic protocol into a 24-h
period (D) failed to induce chimerism and also led to unacceptable toxicity. The conditioning
regimen that was successful in simultaneous kidney and bone marrow transplantation (SKBMT)
failed to induce long-term allograft survival in the delayed tolerance protocol at 4 mo (B). When
anti-CD8 mAb was added to the original regimen, approximately 70% of recipients achieved
long-term survival (A). However, this modified regimen with anti-CD8 mAb was not successful
in recipients of the delayed tolerance protocol at 1 mo (C).
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immunosuppression (Fig.1B). Rapid
homeostatic recovery of CD8 Tmem was
observed (Fig.3A) following conditioning
in these recipients. This homeostatic
recovery was faster than that observed in
SKBMT (data not shown) leading us to
conclude that CD8 Tmems had been
insidiously activated by the kidney allo-
graft but that this had not been detectable
by ELISPOT monitoring of cIFN and
IL-2.
CD8 Depletion
Facilitates the Development
of Donor Cell Chimerism
Since the faster homeostatic recovery of
CD8 Tmem seemed to prevent induction
of chimerism, we added anti-CD8 mAb
to the conditioning regimen. This modi-
fied regimen significantly delayed homeo-
static recovery of CD8 Tmem (Fig.3B)
and most recipients (11/13) successfully
developed mixed chimerism (Fig.3C). If
death from infectious complications is
censored, approximately 70% of recipients
survived long-term following withdrawal
of all immunosuppression (Fig.1A).
These observations suggest that, although
not detected by ELISPOT, CD8 Tmem
had been activated during the four
months following KTx despite the
administration of immunosuppression
potent enough to prevent rejection of the
kidney.
More recently, we have evaluated repla-
cing anti-CD8 mAb in the conditioning
regimen with LFA-3/IgG1 (LFA3Ig) anti-
cipating that the agent will be more readily
available for clinical use. LFA3Ig modu-
lates the function of CD2 (+) and depletes
efficiently primate CD95
+CD28
- Effector
Tmem in vivo. This molecule mediates
cognate interactions between cells expres-
sing human CD2 and CD16 to activate
cells, increase extracellular signal-regulated
kinase phosphorylation, upregulate cell
surface expression of the activation marker
CD25, and induce release of Granzyme
B.
14-17 Three recipients treated with the
modified regimen with LFA3Ig but with
no anti-CD8mAb successfully developed
chimerism and achieved long-term survival
(manuscript in preparation).
Inflammation is Detrimental
to Tolerance Induction
Since our results suggested that Tmem
activation occurs after KTx, we speculated
that a shorter interval between organ
transplantation and DBMT might limit
this response and increase the likelihood
of inducing allograft tolerance. Therefore,
we evaluated DBMT at one month after
KTx in an attempt to identify the optimal
timing of DBMT. As we anticipated,
chimerism induction in recipients who
received DBMT earlier after KTx was
more successful. All seven recipients who
received DBMT at one month developed
excellent chimerism (data not shown). The
fact that two of 13 recipients who received
DBMT at four months failed to develop
any detectable chimerism, suggested that
Tmem activation may indeed be lower
earlier after KTx. However, to our sur-
prise, no recipients of DBMT at one
month achieved renal allograft tolerance
(Fig.1C) despite consistently successful
induction of chimerism. The state of the
inflammatory milieu during the peritrans-
plant period has been shown to impact
the molecular phenotype and function
of alloreactive T cells.
18,19 We therefore
hypothesized that higher proinflammatory
responses during the earlier post-transplant
period adversely affected tolerance induc-
tion. RT-PCR analyses of the peripheral
blood mononuclear cells revealed that
mRNA levels of proinflammatory cytokines
in the recipients who received DBMT at
one month were significantly higher than
those who received DBMT at four months.
LUMINEX assays also showed higher IL-6
and IL-17 levels in the one month group.
These results suggest that the presence
of higher proinflammatory cytokines is
detrimental to tolerance induction.
Figure2. cIFN Tmem responses measure by ELISPOT after KTx. Post KTx anti-donor responses were measured by ELISPOT in various populations, Bulk
(PBMCs), Tmem(CD16
-CD95
+), CD8 Mem(CD16
-CD8
+CD95
+) and CD4 Mem(CD16
-CD4
+CD95
+). Tmem responses declined in a time dependent fashion.
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Conclusion
Tolerance induction several months after
organ transplantation (delayed tolerance)
is feasible via the mixed chimerism
approach with additional modifications
to mitigate Tmem responses that have
been induced by the transplanted allograft.
Timing of delayed DBMT also appeared
to be critical for successful induction of
allograft tolerance, which is affected by
higher inflammatory responses during the
early post-transplant period.
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